or Try an Advanced Search...

    Technical Analysis for RGLS - Regulus Therapeutics Inc.

    Grade Last Price % Change Price Change
    F 1.49 2.05% 0.03
    RGLS closed up 2.05 percent on Friday, November 1, 2024, on 89 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    Earnings due: Nov 7
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Flat
    Historical RGLS trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    BB Squeeze Started Range Contraction 0.00%
    Gapped Up Strength 0.00%
    50 DMA Resistance Bearish 2.05%
    Fell Below 20 DMA Bearish 2.05%
    Fell Below 50 DMA Bearish -4.49%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.49%
    Older End-of-Day Signals for RGLS ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 19 hours ago
    20 DMA Resistance about 22 hours ago
    10 DMA Resistance about 22 hours ago
    Up 3% about 22 hours ago
    Up 2% about 22 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    RGLS Chart by TradingView
    Basic chart:

    Profile

    Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides. Its microRNA development candidates target miR-122 in hepatitis C virus infection; miR-21 and miR-221 in hepatocellular carcinoma; miR-21 in kidney fibrosis; miR-33 in atherosclerosis; and miR-10b in glioblastoma. The company has strategic alliances with AstraZeneca AB, GlaxoSmithKline plc, Sanofi, and Alnylam and Isis, as well as a strategic collaboration with Biogen Idec MA Inc. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Disease Genetics Blastoma Glioblastoma Carcinoma Hepatitis C Hepatitis C Virus Hepatocellular Carcinoma Oligonucleotide RNA Regulus Therapeutics Alnylam Pharmaceuticals Nucleic Acids Atherosclerosis Hepatitis C Virus Infection Nucleotides

    Is RGLS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 29 These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts
    Oct 8 Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Aug 14 Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth
    Aug 8 Regulus Therapeutics GAAP EPS of -$0.17 misses by $0.02
    Aug 8 Regulus: Q2 Earnings Snapshot
    Aug 8 Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
    Aug 6 Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
    Jul 9 Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
    Jun 24 What's Going On With Regulus Therapeutics Stock Monday?
    Jun 24 Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    See more RGLS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.79
    52 Week Low 1.08
    Average Volume 361,606
    200-Day Moving Average 1.86
    50-Day Moving Average 1.58
    20-Day Moving Average 1.52
    10-Day Moving Average 1.49
    Average True Range 0.12
    RSI (14) 46.81
    ADX 12.03
    +DI 18.15
    -DI 16.01
    Chandelier Exit (Long, 3 ATRs) 1.43
    Chandelier Exit (Short, 3 ATRs) 1.76
    Upper Bollinger Bands 1.65
    Lower Bollinger Band 1.38
    Percent B (%b) 0.4
    BandWidth 17.53
    MACD Line -0.02
    MACD Signal Line -0.03
    MACD Histogram 0.0032
    Fundamentals Value
    Market Cap 30.13 Million
    Num Shares 20.2 Million
    EPS -1.59
    Price-to-Earnings (P/E) Ratio -0.94
    Price-to-Sales 7.43
    Price-to-Book 1.12
    PEG Ratio -0.04
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.58
    Resistance 3 (R3) 1.58 1.55 1.57
    Resistance 2 (R2) 1.55 1.53 1.55 1.56
    Resistance 1 (R1) 1.52 1.51 1.51 1.52 1.55
    Pivot Point 1.49 1.49 1.48 1.49 1.49
    Support 1 (S1) 1.46 1.47 1.45 1.46 1.43
    Support 2 (S2) 1.43 1.45 1.43 1.42
    Support 3 (S3) 1.40 1.43 1.42
    Support 4 (S4) 1.40